You Position: Home > Paper
The expression of NF-κB p50 and its relationship with apoptosis in breast carcinoma
( views:206, downloads:24 )
- Author:
- No author available
- Journal Title:
- CANCER RESEARCH AND CLINIC
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1006-9801.2006.05.005
- Key Word:
- 乳腺癌;转录因子-κBp50;细胞凋亡
Abstract： 目的研究核转录因子-κB p50(NF-κB p50)在乳腺癌组织中的表达和意义及其与细胞凋亡的关系.方法应用Elivision免疫组化染色法和脱氧核糖核酸末端转移酶介导的缺口末端标记(TUNEL)技术,对65例乳腺癌组织中NF-κB p50、凋亡细胞表达进行原位观察和比较,并结合临床资料进行分析.结果 65例乳腺癌标本NF-κB p50表达阳性率为70.8%(46/65),细胞凋亡指数(AI)为(4.59±1.94)%;NF-κB p50表达强度与患者的肿瘤的大小、组织分级、孕激素受体(PR)无关(P＞0.05);与腋淋巴结转移数、雌激素受体(ER)状况明显相关(P＜0.05).NF-κB p50表达阴性的乳腺癌中AI明显高于NF-κB p50表达阳性组(P＜0.05).NF-κB p50活性强度与AI呈明显的负相关(P＜0.001).结论 NF-κB p50的异常激活在早期乳腺癌的发生和转化中起重要作用,其抑制凋亡活性与肿瘤侵袭转移及恶性潜能密切相关,对NF-κB p50活性及细胞凋亡的检测有助于乳腺癌的临床分析,并有望成为预后的观察指标.
- [1]吴斌,时德,杨国凯.大肠癌组织中核因子-κB、C-myc和ICAM-1的表达及意义[J].2004,(2).
- [2]Miranda M,Grillo M,Rosfjord EC,etc.Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.[J].2006,95(2).
- [3]Ranjan Sen,David Baltimore.Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism[J].1986,47(6).
- [4]Marty W. Mayo,Cun-Yu Wang,Patricia C. Cogswell,etc.Requirement of NF-κB Activation to Suppress p53-Independent Apoptosis Induced by Oncogenic Ras[J].1997,278 (5344).
- [5]Baldwin AS.Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.[J].2001,107(3).
- [6]Niu MY,White D,Menard M,etc.Estrogen withdrawal-induced NF-kappa B activity and Bcl-3 expression in breast cancer cells: Roles in growth and hormone independence[J].2003,23(19).
- [7]Sovak M A,Bellas R E,Kim D W,etc.Aberrant nuclear factor-kappaB\/Rel expression and the pathogenesis of breast cancer.[J].1997.
- [8]Z, Gatalica,S M, Lele,B A, Rampy,etc.The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.[J].2000,88(6).